Nonsurgical management of gallbladder cancer: cytotoxic treatment and radiotherapy

References

• Pitt HA, Dooley WC, Yeo CJ, Cameron JL. Malignancies of the biliary tree. C1.117: Probl Surg: 32,1-8 (1995).
   Google Scholar
• Jones RS. Carcinoma of the gallbladder. Surg. Gun. North Am 70,1419–1425 (1990).
   PubMedGoogle Scholar
• Kochi W, Masao T, Koji Y eta]. Carcinoma and polyps of the gallbladder associated with Peutz-Jeghers syndrome. Dig. Dis. Sc]. 32,943–948 (1987).
   Google Scholar
• Sumiyoshi K, Nagai E, Chijiiwa K, Nakayama E Pathology of carcinoma of the gallbladder. Surg 15(3), 315–321 (1991).
   Google Scholar
• Chao TC, Graeger JA. Primary carcinoma of the gallbladder. J. Surg. Oncol 46(4), 215–221 (1991).
   Google Scholar
• Pichlmayr R, Lamesch P, Weimann A et al. Surgical treatment of cholangiocellular carcinoma. Worldj Surg. 19,83–88 (1995).
   PubMedGoogle Scholar
• KLapdor R. Perspectives in chemotherapy of pancreatic cancer. Eur j Surg: Oncol 17(2), 153–166. (1991)
   PubMedGoogle Scholar
• Iwasaki Y, Todoroki T, Fukao K et al. The role of intraoperative radiation therapy in the treatment of bile duct cancer. World Surg: 12,91–98 (1988).
   PubMed Web of Science ®Google Scholar
• Herskovic A, Heaston D, Eugler MJ eta]. Irradiation of biliary carcinoma. Radiology 139,219–222 (1981).
   Google Scholar
• Venu RP, Geenen JE, Hogan WJ eta]. Intraluminal radiation therapy for biliary tract malignancy — an endoscopic approach. Gastrointestinal Endoscopy33,236–238 (1987).
   Google Scholar
• Wieman TJ, Spanos WJ. Endoscopic implantation of iridium wire for treatment of carcinoma of the biliary duct. Am. J. Surg: 155,616-618 (1988).
   Google Scholar
• Vaittinen E. Carcinoma of the gallbladder: A study of 390 cases diagnosed in Finland 1953–1967. Ann. Chir. Cynaecol Fenn. 59\(Suppl. 168), 7–31 (1970).
   Google Scholar
• Bosset JF, Mantion G, Gillet M et al. Primary carcinoma of the gallbladder: Adjuvant postoperative external irradiation. Cancer64, 1843–1847 (1989).
   PubMedGoogle Scholar
• Fields JN, Emani B. Carcinoma of the extrahepatic biliary system - results of primary and adjuvant radiotherapy. Int. J. Radial. Chiral Bid Phys. 13,331–338 (1987).
   PubMed Web of Science ®Google Scholar
• Houry S, Schlienger M, Huguier M et al. Gallbladder carcinoma: role of radiation therapy. Br. Surg. 76,448-450 (1989).
   Google Scholar
• ••Twenty patients with gallbladdercarcinoma were treated with radiotherapy (mean total dose 4200 radiation absorbed dose). There was no difference in survival between patients treated or not treated with additionally chemotherapy. This experience is the largest published and suggests that radiotherapy may increase survival after no resection or palliative resection of gallbladder carcinoma.
   Google Scholar
• Kopelson G, Harisiadis L, Tretter P et al. The role of radiation therapy in cancer of the extra-hepatic biliary system. An analysis of 13 patients and a review of the literature of the effectiveness of surgery, chemotherapy and radiotherapy. int. J. Radial. Oncol Biol. Phys. 2,883-895 (1977).
   Google Scholar
• Smoron GL. Radiation therapy of carcinoma of the gallbladder and biliary tract. Cancer 40, 1422–1431 (1977).
   PubMedGoogle Scholar
• Tredwell TA, Hardin WJ. Primary carcinoma of the gallbladder. The role of adjunctive therapy and its management. Am.j Surg. 132,703–708 (1976).
   Google Scholar
• Flickinger JC, Epstein AN, Iwatsuki S et al Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 6(2), 289–294 (1991).
   Google Scholar
• Buskirk SJ, Gunderson LL, Adson MA et al Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma. Int. J. Rad Oncol Biol. Physiol 10,2013–2023 (1984).
   PubMed Web of Science ®Google Scholar
• Tokoroki T, Iwasaki Y, Orii K et al. Resection combined with intraoperative radiation therapy (TORT) for stage IV (TNM) gallbladder carcinoma. World Surg: 15,357–366 (1991).
   PubMedGoogle Scholar
• Busse PM, Cady B, Bothe A, Jr. et al. Intraoperative radiation therapy for carcinoma of the gallbladder. Worldj Surg. 15(3), 352–356 (1991).
   Google Scholar
• Guerrero RC, Abello EJ, Custodio D, Diego ES. Chemotherapy of Cancer Mitomycin C. JPMA 48,559–564 (1972).
   Google Scholar
• Moertel CG. The gallbladder. In: Cancer Medicine. Holland JF, Frei IE (Eds.), Lea and Febiger, Philadelphia, USA, 1547–1551 (1973).
   Google Scholar
• Taal BG, Audisio RA, Bleiberg H eta]. Phase II trial of mitomycin C in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cooperative Group Study. Ann. Oncol 4,607–611 (1993).
   Google Scholar
• Davis HLJ, Ramirez G, Ansfield FJ. Adenocarcinomas of stomach, pancreas, liver and biliary tracts. Cancer 33,193–197 (1974).
   Google Scholar
• Falkson G, Macintyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer54, 965–969 (1984).
   Google Scholar
• Takada T, Uchiyama K. Chemotherapy for unresectable biliary cancer. Kann Tan Sui 25,695–699 (1992).
   Google Scholar
• Okada S, Ishii H, Nose H et al. A Phase II study of cisplatin in patients with biliary tract carcinoma. Oncology51,515–517 (1994).
   PubMedGoogle Scholar
• Jones DVJ, Lozani R, Hogue A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. Clin. Oncol 14,2306–2310 (1996).
   Google Scholar
• Mezger J, Sauerbruch T, Ko Y et al. Phase II trial of gemcitabine in biliary tract cancers. Proc. Am. Soc. Gun. Oncol Abstract 1059 (1997).
   Google Scholar
• Dragovich T, Ramanathan RK, Remick S et al Phase II trial of a meekly 150-minute gemcitabine infusion in patients with biliary tree carcinomas. ASCOAbstract 1159 (2000).
   Google Scholar
• Gallardo J, Rubio B, Fodor et al. Gemcitabine (GEM): an active drug in advanced gallbladder cancer (AGC). ASCO Abstract 1042 (2000).
   Google Scholar
• •Twenty-five chemonaïve patients with measurable locally advanced or metastatic gallbladder cancer were treated with gemcitabine. There was no complete response, but eight partial responses resulting in an overall response rate of 42%. Median survival time from diagnosis was 24.6 weeks, 40% of patients survived >6 months, 1-year survival was 16%.
   Google Scholar
• Lozano RD, Patt YZ, Hassan MM et al. Oral Capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer) . ASCO Abstract 1025 (2000) .
   Google Scholar
• •In a pilot trial eight patients with nonresectable gallbladder cancer were treated with capecitabine. Radiological overall response rate was 50% and the 1-year overall survival rate was 100%.
   Google Scholar
• Hall SH, Benjamin RS, Murphy WK et Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44,2008–2013 (1974).
   Google Scholar
• Okada S, Okusaka T, Ishii H et al. Phase II trial of cisplatin, epirubicin and continuous infusion 5-fluorouracil (5-FU) (CEF therapy) for advanced gallbladder cancer (GBC). ASCOAbstract 1072 (1997).
   Google Scholar
• Kato K, Koike A, Koide T et al. Efficacy of 48-hour infusion of 5-fluorouracil for gallbladder cancer. Jpn. j Cancer Chemother. 20,2341-2344 (1993).
   Google Scholar
• Moertel CG, Rubin J, O'Connell M et al. A Phase II study of combined 5-fluorouracil, doxorubicin, cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. j Clin. Oncol 4(7), 1053–1057 (1986).
   Google Scholar
• Kajanti M, Pyrhonen S. Epirubicin- sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A Phase II study. Am. J. Clin. Oncol 17,223–226 (1994).
   Google Scholar
• Takada F, Kutott A, Matsushiro T et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin with 5-fluorouracil alone in treatment of pancreatic-biliary carcinoma. Oncology51, 396–402 (1994).
   PubMed Web of Science ®Google Scholar
• Silk YN, Douglas HO, Nava HR. Carcinoma of the gallbladder. The Roswell Park experience. Ann. Surg: 210,751-759 (1989).
   Google Scholar
• Kemeny NE. Regional chemotherapy of colorectal cancer. Eur. J. Cancer 31A(7–8), 1271–1276 (1995).
   Google Scholar
• Hohn D, Melnick J, Stagg R et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. j Clin. Oncol 3(1), 98–102 (1985).
   Google Scholar
• Northover JM, Terblanche J. A new look at the arterial supply of the bile duct in man and its surgical implications. BE J. Surg. 66(6), 379–384 (1979).
   Google Scholar
• Makela JT, Kairaluoma MI. Superselective intraarterial chemotherapy with mitomycin for gallbladder cancer. BE J. Swg. 80,912-915 (1993). A group of 27 patients with carcinoma of the gallbladder was treated by superselective intra-arterial chemotherapy with mitomycin. The overall response rate to intra-arterial chemotherapy was 48%. The median survival time for responders was 34 months and for nonresponders 8 months.
   Google Scholar
• Smith GW, Bukowski RM, Hewlett JS, Groppe CW. Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer54, 1513–1516 (1984).
   PubMed Web of Science ®Google Scholar
• Seeger J, Woodcock TM, Blumenreich MS et al. Hepatic perfusion with FUdR utilizing an implantable system in patients with liver primary cancer or metastatic cancer confined to the liver. Cancer Invest. 7,1–6 (1989).
   PubMed Web of Science ®Google Scholar
• Fukuda S, Okuda K, Kinoshita H et al. Study of hepatic arterial chemoinfusion with continous CDDP, 5-FU, low dose administration for advanced gallbladder cancer. Jpn. j Cancer Chemother 23,1610–1613 (1996).
   Google Scholar
• Kairaluoma MI, Leinonen A, Niemela R, Kiviniemi H, Siniluoto T, Stahlberg M. Superselective intra-arterial chemotherapy with mitomycin C in liver and gallbladder cancer. Eur. j Surg. Oncol 14,45–50 (1988).
   PubMedGoogle Scholar
• Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur. J. Cancer 34(7), 977–986 (1998).
   Google Scholar
• Glimelius B, Hoffmann K, Sjöden PO eta]. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol 7,593–600 (1996).
   Google Scholar
• Bosset JF, Mantion G, Gillet M et al. Primary carcinoma of the gallbladder: adjuvant postoperative external irradiation. Cancer 64,1843–1848 (1989).
   PubMedGoogle Scholar
• Mahe M, Stampfli C, Romestaing P et al. Primary carcinoma of the gallbladder: potential for external radiation therapy. Radiother. Oncol 33,204–208 (1994).
   PubMedGoogle Scholar
• Alberts SR, Mahoney MR, Fishkin PA et al. Toxicity of irinotecan (CPT-11) in patients with advanced gallbladder (GB) or biliary (BILI) tumors: A North Central Cancer Treatment Group (NCCTG) study. ASCO Abstract 1166 (2000).
   Google Scholar
• Agelaki S, Papakostas P, Stathopoulos G et al Phase II study of docetaxel with g-csf support as first-line treatment for unresectable or advanced biliary tract carcinoma: a multicenter Phase II trial. ASCO Abstract 1058 (1999).
   Google Scholar
• Misra NC, Jaiswal MS, Singh RV, Das B. Intrahepatic arterial infusion of combination of mitomycin C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. Cancer 39, 1425–1429 (1977).
   PubMed Web of Science ®Google Scholar
• Von Eyben F, Hellekant C, Mattsson W, Ljungquist U, Jonsson K. Mitomycin C in advanced gallbladder carcinoma. Oncology 19,81–84 (1980).
   Google Scholar
• Miyamoto H, Ogawa M, Inagaki J, Horikoshi N. Arterial infusion of combination chemotherapy using adriamycin and mitomycin C for hepatoma and metastatic tumor of the liver. Jpn. J. Cancer Chemother. 9,1955–1960 (1982).
   PubMedGoogle Scholar
• Horoichi Y, Matsuoka S, Ina K, Nagai H, Matsuura T, Suga S. A case of gallbladder cancer successfully treated with UFTM therapy. IRYO 41, 1069–1073 (1987).
   Google Scholar
• Sokoto Y, Fukushi G, Tsushima K et al MQF-FT and MQF-UFT in gallbladder and bile duct cancer. Jpn. j Cancer Chemother. 15,2731–2735 (1988).
   PubMedGoogle Scholar
• Iba T, Fukunaga T, Sugiyama K et al. A case of gallbladder cancer with marked response to EAP treatment. Jpn. j Cancer Chemother. 19,897–900 (1992).
   PubMedGoogle Scholar
• Feun LG, Blyden G, Yrizarry J et al Clinical and pharmacological study of intrahepatic artery infusion of thiotepa. Cancer Blather. 8,43–48 (1993).
   PubMedGoogle Scholar
• Inoue M, Onda M, Tajiri T et al. Two cases of improved quality of life with intra-arterial infusion of CDDP for unresectable gallbladder and pancreatic cancer. Jpn. J. Cancer Chemother. 20, 1676–1678 (1993).
   PubMedGoogle Scholar
• Colleoni M, Di Bartolomeo M, Di Leo A et al Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur. Cancer31A, 2427–2428 (1995).
   PubMedGoogle Scholar
• Lokich J, Anderson N, Moore C et al Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) ± etoposide. j Infus. Chemother. 6(1), 43–46 (1996).
   Google Scholar
• Gebbia V, Majello E, Testa A et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Result of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer 78, 1300–1307 (1996).
   Google Scholar
• ••In this multicenter Phase II trial with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil in modulation with intravenous high-dose levofolinic acid and oral hydroxyurea, 9 of 30 patients with advanced gallbladder carcinoma had a partial response (30%; 95% CL: 26-34%) with a median duration of 6.5 months, and eight (27%) had stabilization of disease. Median overall survival was 8 months.
   Google Scholar
• Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A Phase II study of 5-fluorouracil, leucovorin and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82, 2321–2325 (1998).
   Google Scholar
• Pall YZ, Jones DVJ, Hogue A et al. Phase II trial of intravenous fluorouracil and subcutaneous interferon a-2b for biliary tract cancer. 1 Clin. Oncol. 14, 2311–2315 (1996).
   Google Scholar